CARIS LIFE SCIENCES INC
CAINASDAQTrading Snapshot
- Day Range
- $22.15 – $22.57
- 52-Week Range
- $14.19 – $42.50
- Volume
- $2.90B
- Avg Volume
- $2.86B
- Shares Outstanding
- 282.7M
- Next Earnings
- Oct 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $812M
- Last Q Revenue
- $264M
- P/E Ratio
- 59.7
- P/S Ratio
- 6.3x
- EPS (TTM)
- $0.37
- Dividend Yield
- 0.00%
Why Investors Own CAI
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CARIS LIFE SCIENCES INC
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-11. The following slide deck was published by Caris Life Sciences, Inc.
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Caris Life Sciences (CAI) Q2 beats with raised guidance, margin expansion and Caris Detect launch.
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsJ.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences (NASDAQ:CAI)
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est
Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.030 billion-$1.040 billion vs $1.003 billion estimate.